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A DEDICATED TRANSPLANT INFORMATICS TEAM ENHANCES QUALITY,
SAFETY, AND COMPLIANCE OUTCOMES
Batterson, L.K., Geerdes, P.A. Mayo Clinic - Rochester, Rochester, MN
Purpose: The success of the Transplant Center Informatics Team
will position the Blood and Marrow Transplant (BMT) Program
to provide the best care to each patient every day and advance the
practice of transplantation.
Annually approximately 400 patients are transplanted. The ex-
pected outcomes for the Transplant Informatics BMT Program are:
Improvement in quality of data management throughout the
transplant continuum of care.
Enhanced communication flow through the various entities to en-
able achievement of transplant patient outcomes.
Ability to achieve outstanding rankings for regulatory compliance
and exceptional quality metrics.
Methods: PDSAmethodology began with reviewing the key data el-
ements of each form, the data source of the information, the time
needed to complete each form, and the validation process prior to
submission. Crucial areas identified were the number of manual
data points to obtain the information and ongoing assessment of
our current database repository of information. The team developed
training references to ensure an understanding of each of the key data
elements and the importance of verifying and validating the data. The
teamcreated a streamlinedprocess to ensure data integrity in order to
ensure wemeet regulatory compliance for accurate form submission.
Results: The process improvement projects allowed the Transplant
Informatics team to receive outstanding rankings for regulatory
compliance and exceptional quality metrics on 100% form submis-
sion. The process assisted with timely protocol updates and success-
ful management of patient outcomes. Continuous validation and
audits of our process have ensured our meeting the expectations of
value and safety for our patients.
Table. BMT Volume and Patient Survival 2005 -2010
2005 2006 2007 2009 2010Patient Survival @ 100 Days 94.6% 94.3% 93.8% 95.4% 96%
Patients Survival @ 1 Year 83.6% 86.7% 82.5% 83.1% 86%
Number BMT Transplants 354 332 320 349 373
Number of BMT Appointments 3639 3638 3172 3072 3743
Total Number of BMT Forms 1867 3475 2755 4317 4860
Percent Forms Completed 5.8% 5.0% 5.0% 100% 100%Conclusion: This process improvement initiative has increase effi-
ciency of data management. The Transplant Database Team
achieved 100% submission of regulatory forms. It has also achieved
greater than expected patient outcomes for one year post transplant
survival.
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THE INCIDENCE OF NEW MALIGNANCY IN PATIENTS WITH ACUTE LEU-
KAEMIA TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) 1971 – 2006. A RETROSPECTIVE NATIONAL
COHORT STUDY
Larsen, H.B.1, Petersen, H.2, Roepstorff, C.2, Berthelsen, A.-M.2,
Sengeløv, H.2, Heilmann, C.1 1Rigshospitalet, Copenhagen, Denmark;
2Rigshospitalet, Copenhagen, Denmark
Background: Patients treated with allogeneic HSCT have an in-
creased risk of later acquiring new malignancy. The risk is linked
to treatment with chemotherapy, irradiation and immunosuppres-
sive drugs. The increased risk of new malignancy has been estimated
to four to eleven fold.
Purpose: The purpose was to describe the incidence of new malig-
nancy among Danish patients treated for acute leukemia by alloge-
neic HSCT. Post Transplant Lymphoprolifretive Disase was not
included in the analysis.
Methods:This retrospective study covers all Danish patients (adults
and children) diagnosed with acute leukaemia and treated with mye-
loablative HSCT in the period April 14th 1971 – Jan 1st 2006. Ac-
cording to the Danish Act on the Civil Registration System (CPR)
all Danes are assigned a personal identification number by birth al-lowing for centralized nationwide registation of personal data. The
CPR provides centralized acces to all hospital admission, pathology
reports and limited access to medical files and death. Accordingly,
data collection is based to pathology and death reports for all patients
treated with HSCT.
Results: A total of 460 patients with acute leukaemia were treated
with allogeneic HSCT. Of these, 27 (5,9%) were diagnosed with
a new malignancy. Of the 27 patients 2 (7%) were diagnosed with
a hematologic cancer (leukaemia/MDS), 25 (93%) with solid tumors.
The site of the tumors were CNS (n5 6), skin (n5 4), lung (n5 3),
pancreas (n5 2), oral (n5 2), thyroid (n5 2), cervix (n5 2), uterus
(n 5 1), osephagus (n 5 1), prostate (n 5 1), unknown (n 5 1). In
fourteen (52%) of the 27 patients, the new malignancy was the pri-
mary cause of death.
The median time from HSCT to diagnosis of a new malignancy
was 3707 days (10.16 years) (range 32 days -7684 days). The inci-
dence of a new malignancy was 2% (n 5 7) at 5 year, 2.8% % (n 5
13) at 10 years, 4.8% (n5 22) at 15 years, 5.7% (n5 26) at 20 years
and 5.9 (n5 27) at 25 years. Of the 27 patients diagnosed with a new
malignancy, 23 (85%) were conditioned with TBI and 8 (30%) were
also diagnosed with ChGvHD.
Conclusion: In this Danish cohort of acute leukemia patients
treated with HSCT the incidence of a new malignancy was 6%
and 3% of the total population (n 5 460) died as a result of this
new malignancy. The advantage of this study is a centralized access
to pathology and death information for all patients treated and living
in Denmark. The centralized access to information allows high qual-
ity and minimizes problems with incomplete data.
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CIBMTR MONTHLY INTERNAL ASSESSMENT IMPROVES QUALITY OF
REGISTRY DATA
Minas, N.M., Ruehle, K. University of Maryland Medical Center, Balti-
more, MD
Background: Important health decisions about oncology are often
based on data, therefore the accuracy of data used in decision-making
is of utmost importance. Further, inaccurate data can affect the re-
sults of studies and eventually lead to invalid results. To ensure the
highest degree of accuracy of CIBMTR (Center for International
Blood and Marrow Transplant Research) data, the University of
Maryland Blood and Marrow Transplant team implemented an ad-
ditional internal monthly assessment to ensure the validity and qual-
ity of registry data collected.
Methods: The Blood and Marrow Transplant Program Manager
and data managers developed an internal assessment tool to assess
for discrepancies in the following data points collected about pa-
tients: 1) date of engraftment of absolute neutrophil count, 2) date
of engraftment of platelets, 3) onset of acute graft versus host disease
(GVHD), 4) onset of chronic GVHD, 5) diagnosis date, 6) condi-
tioning regimen, 7) disease status, 8) Karnofsky performance status,
9) transplant date, and 10) latest follow-up date. From February to
July of 2011 the CIBMTR forms of four subjects per month (40%)
were randomly selected for audit. These forms were then audited us-
ing an original internal assessment form by the data managers.
Results: The percentage of data accuracy for each data point mea-
sured ranged from 60% to 100%, with engraftment of platelets scor-
ing the lowest. The accuracy of diagnosis date, Karnofsky
performance status and latest follow-up date ranged from 67% to
77%. The accuracy of the remaining data points were greater than
90%. Corrective action was taken by reviewing all CIBMTR forms
with ‘‘engraftment of platelets’’ responses and correcting the data
in the electronic database. This was repeated for all data points
with less than 100% accuracy rate. Common causes of inaccurate
data included the recording of transfusion dates other than platelet
infusions, incorrect timing of follow-up dates and difficulty obtain-
ing pathology reports from referring physicians.
Conclusions: The internal audit process demonstrated that despite
following standardCIBMTRprocesses for data entry, some data was
inaccurate. Utilization of an additional monthly internal assessment
resulted in a higher degree of accuracy. The CIBMTR monthly in-
ternal assessment of data is now routinely performed in our organi-
zation. Organizations that do not currently perform regular internal
auditing for accuracy of CIBMTR data may want to consider this.
